Willingness to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians, Oct 2021 (% of respondents)
Data was provided to Insider Intelligence by Cowen & Company.
Data is from the February 2022 Cowen & Company "Physician Survey on Prescription Digital Therapeutics." 200 US physicians were surveyed during September-October, 2021, spanning across four indications: type 2 diabetes, pediatric attention-deficit/hyperactivity disorder (ADHD), substance use and opioid disorder, and chronic insomnia. The five products around which the survey centered are BT-001 (Better Therapeutics), EndeavorRx (Akili Interactive), reSET and reSET-O (Pear Therapeutics), and Somryst (Pear Therapeutics). This list is not exhaustive of all PDTs, either approved or in development. Cowen & Company, LLC and/or its affiliates make a market in the stock of Better Therapeutics and Pear Therapeutics securities.